US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q32 Bio Inc.

1.62

+0.06003.85%

Volume:80.41K

Turnover:129.16K

Market Cap:19.76M

PE:-0.25

High:1.64

Open:1.53

Low:1.53

Close:1.56

Loading ...

Overview Company News Filings

Q32 Bio granted Fast Track designation for bempikibart

BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics

THOMSON REUTERS

Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

THOMSON REUTERS

BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial

Q32 Bio Inc - Expects Signal-Aa Part B Data in 1H'26

THOMSON REUTERS

Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

THOMSON REUTERS

BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC Filing

Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures

Q32 Bio Q4 2024 GAAP EPS $(1.16) Beats $(1.51) Estimate, Cash And Cash Equivalents Of $78M As Of December 31, 2024 Expected To Provide Financial Runway Into 2H 2026

Press Release: Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results From Signal-Aa Part a Clinical Trial Evaluating Bempikibart in Patients With Alopecia Areata at the 2025 American Academy of Dermatology Meeting

THOMSON REUTERS

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Inc expected to post a loss of $1.51 a share - Earnings Preview

Q32 Bio Announces Late-Breaking Presentation of Results From Signal-Aa Part a Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

THOMSON REUTERS

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/QTTB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QTTB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":1.62,"timestamp":1746201437814,"preClose":1.56,"halted":0,"volume":80409,"delay":0,"floatShares":4728923,"shares":12197615,"eps":-6.578484,"marketStatus":"Trading","change":0.06,"latestTime":"05-02 11:57:46 EDT","open":1.53,"high":1.635,"low":1.53,"amount":129155.7742377,"amplitude":0.067308,"askPrice":1.63,"askSize":442,"bidPrice":1.61,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-6.578484,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746216000000},"marketStatusCode":2,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":1.56,"preHourTrading":{"tag":"盘前","latestPrice":1.53,"preClose":1.56,"latestTime":"09:29 EDT","volume":3578,"amount":5517.719672,"timestamp":1746192598425},"postHourTrading":{"tag":"盘后","latestPrice":1.51,"preClose":1.56,"latestTime":"19:51 EDT","volume":3655,"amount":5572.93,"timestamp":1746143484376},"volumeRatio":0.525053,"impliedVol":0.5983,"impliedVolPercentile":0.226},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","floatShares":4728923,"roa":"-59.28%","roe":"--","lyrEps":-5.12108,"volumeRatio":0.525053,"shares":12197615,"dividePrice":0,"high":1.635,"amplitude":0.067308,"preClose":1.56,"low":1.53,"week52Low":1.38,"pbRate":"3.48","psRate":"-1.35","week52High":53.79,"institutionHeld":0,"latestPrice":1.62,"committee":-0.049881,"eps":-6.578484,"divideRate":0,"volume":80409,"delay":0,"ttmEps":-6.578484,"open":1.53,"prevYearClose":3.44,"prevWeekClose":1.87,"prevMonthClose":1.6,"prevQuarterClose":1.65,"fiveDayClose":1.87,"twentyDayClose":1.6,"sixtyDayClose":3.36},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QTTB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531033277","title":"Q32 Bio granted Fast Track designation for bempikibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033277?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:21","pubTimestamp":1746012083,"startTime":"0","endTime":"0","summary":"Q32 Bio (QTTB) announced that the FDA has granted Fast Track designation to Q32 Bio’s bempikibart for the treatment of AA. Bempikibart is a fully h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/q32-bio-granted-fast-track-designation-for-bempikibart?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/q32-bio-granted-fast-track-designation-for-bempikibart?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4567","BK4153","IE00B5TLWC47.USD","BK4139","IE00BFXG0V08.USD","QTTB","IE00BYQQ9H92.USD","AA","BK4104","FAST","BK4588"],"gpt_icon":0},{"id":"2531338000","title":"BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2531338000","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531338000?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:17","pubTimestamp":1746011843,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia AreataApril 30 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO ANNOUNCES FDA FAST TRACK DESIGNA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6R50WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2531038831","title":"Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038831","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531038831?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:59","pubTimestamp":1746010740,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata  and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration  has granted Fast Track designation  to Q32 Bio's bempikibart  for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-announces-fda-fast-105900537.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-announces-fda-fast-105900537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FAST","AA","BK4588","IE00B5TLWC47.USD","QTTB","BK4567","BK4585","ADX","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4153","BK4104"],"gpt_icon":0},{"id":"2530319849","title":"BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530319849","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530319849?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:54","pubTimestamp":1745614493,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025April 25  - Inhibikase Therapeutics Inc IKT.O:Q32 BIO INC - MARK IWICKI RESIGNS FROM Q32 BIO BOARD EFFECTIVE DEC 31, 2025Q32 BIO INC - IWICKI RESIGNS TO FOCUS ON CEO ROLE AT INHIBIKASE THERAPEUTICSSource text: [ID:n0001193125-25-096703]Further company coverage: IKT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139","IKT"],"gpt_icon":0},{"id":"2530167977","title":"Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2530167977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530167977?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611541,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","QTTB","BK4139"],"gpt_icon":0},{"id":"2530167971","title":"Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530167971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530167971?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611541,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","IKT"],"gpt_icon":0},{"id":"2527294200","title":"BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527294200","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527294200?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:07","pubTimestamp":1744801647,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A TrialApril 16 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO DOSES FIRST PATIENTS IN BOTH PART A OPEN-LA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2527993291","title":"Q32 Bio Inc - Expects Signal-Aa Part B Data in 1H'26","url":"https://stock-news.laohu8.com/highlight/detail?id=2527993291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527993291?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:59","pubTimestamp":1744801142,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2527939291","title":"Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2527939291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527939291?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:59","pubTimestamp":1744801142,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2526614647","title":"BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526614647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526614647?lang=en_us&edition=fundamental","pubTime":"2025-04-12 05:53","pubTimestamp":1744408384,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC FilingApril 11 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILINGSource text: [ID:n0001193125-25-079136]Further company coverage: QTTB.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP11I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2518376540","title":"Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures","url":"https://stock-news.laohu8.com/highlight/detail?id=2518376540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518376540?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:00","pubTimestamp":1741759252,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc (QTTB) has disclosed a new risk, in the Trade Secrets category. Q32 Bio Inc faces significant risks related to the protection and poten...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/q32-bio-incs-intellectual-property-challenges-navigating-risks-and-competitive-pressures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/q32-bio-incs-intellectual-property-challenges-navigating-risks-and-competitive-pressures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2518714210","title":"Q32 Bio Q4 2024 GAAP EPS $(1.16) Beats $(1.51) Estimate, Cash And Cash Equivalents Of $78M As Of December 31, 2024 Expected To Provide Financial Runway Into 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2518714210","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518714210?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:00","pubTimestamp":1741690852,"startTime":"0","endTime":"0","summary":"Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.51) by 23.18 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44242801/q32-bio-q4-2024-gaap-eps-1-16-beats-1-51-estimate-cash-and-cash-equivalents-of-78m-as-of-december-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Q32 Bio Q4 2024 GAAP EPS $(1.16) Beats $(1.51) Estimate, Cash And Cash Equivalents Of $78M As Of December 31, 2024 Expected To Provide Financial Runway Into 2H 2026","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2518714614","title":"Press Release: Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518714614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518714614?lang=en_us&edition=fundamental","pubTime":"2025-03-11 18:59","pubTimestamp":1741690740,"startTime":"0","endTime":"0","summary":"-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata  data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology  Annual Meeting --. -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension  and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 --. WALTHAM, Mass., March 11, 2025 /PRNewswire/ -- Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.-- Presented results from SIGNAL-AA Phase 2a Part A clinical trial of. bempikibart in alopecia areata  as a late-breaking oral presentation. at the 2025 American Academy of Dermatology  Annual Meeting. The. the SIGNAL-AA Phase 2a clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","QTTB","BK4139","BK4585","BK4153","AA"],"gpt_icon":0},{"id":"2518546447","title":"Q32 Bio Presents Results From Signal-Aa Part a Clinical Trial Evaluating Bempikibart in Patients With Alopecia Areata at the 2025 American Academy of Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518546447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518546447?lang=en_us&edition=fundamental","pubTime":"2025-03-09 00:00","pubTimestamp":1741449605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nTUAB4QRFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2518440883","title":"Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440883","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518440883?lang=en_us&edition=fundamental","pubTime":"2025-03-09 00:00","pubTimestamp":1741449600,"startTime":"0","endTime":"0","summary":"-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata  --. -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing --. -- Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 --. WALTHAM, Mass., March 8, 2025 /PRNewswire/ --Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata  a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-presents-results-signal-160000777.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-presents-results-signal-160000777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","PK","BK4117","BK4153","QTTB","BK4139","BK4181","BK4218","AFG","BK4107","AA","BK4588"],"gpt_icon":0},{"id":"2517438439","title":"Q32 Bio Inc  expected to post a loss of $1.51 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438439","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438439?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:31","pubTimestamp":1741354266,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  expected to post a loss of $1.51 a share - Earnings Preview Q32 Bio Inc QTTB.OQ QTTB.O is expected to show no change in quarterly revenue when it reports  results on March 11 (estimated) ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ172:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2514322925","title":"Q32 Bio Announces Late-Breaking Presentation of Results From Signal-Aa Part a Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322925","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUAQRQKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2514532225","title":"Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514532225","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514532225?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata  --. WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ --Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata  will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology  Annual Meeting, taking place March 7-11 in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling for the treatment of AA currently being evaluated in a Phase 2 program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-announces-breaking-presentation-140000526.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-announces-breaking-presentation-140000526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","AA","BK4153","BK4117","BK4585","BK4588","BK4107","QTTB","BK4139"],"gpt_icon":0},{"id":"2514391248","title":"Q32 Bio to Participate in Upcoming March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514391248","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514391248?lang=en_us&edition=fundamental","pubTime":"2025-02-26 19:59","pubTimestamp":1740571140,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March:. TD Cowen 45th Annual Health Care ConferenceDate: Wednesday, March 5, 2025Presentation Time: 11:50 a.m. E.T.Location: Boston, MA. Leerink Partners Global Healthcare ConferenceDate: Tuesday, March 11, 2025Fireside Chat Presentation Time: 11:20 a.m. E.T.Location: Miami Beach, FL. A webcast of the presentations will be available on the Events and Presentations page of Q32 Bio's website at www.Q32Bio.com. Archived replays will be available for 90 days following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-participate-upcoming-march-115900589.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-participate-upcoming-march-115900589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2511626015","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2511626015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511626015?lang=en_us&edition=fundamental","pubTime":"2025-02-13 13:40","pubTimestamp":1739425249,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics (VYGR – Research Report), Q32...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-q32-bio-qttb-and-vaxcyte-pcvx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-q32-bio-qttb-and-vaxcyte-pcvx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","QTTB","PCVX","VYGR","BK4137","BK4139","LU0053671581.USD","HCSG"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QTTB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-11","symbol":"QTTB","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2024-05-09","symbol":"QTTB","fiscalQuarterEnding":"2024/03","expectedEps":-1.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-13.15},{"market":"US","date":"2024-03-26","symbol":"QTTB","defaultRemindTime":1711459800000,"type":"split","dateTimestamp":1711425600000,"forFactor":18,"toFactor":1,"ratio":18},{"market":"US","date":"2024-03-13","symbol":"QTTB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"QTTB","fiscalQuarterEnding":"2023/09","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QTTB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QTTB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":4,"updateTime":1739332800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QTTB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QTTB","date":"2025-05-01","current":-0.408861,"percent":0.976378,"low":-10.694771,"twenty":-8.94268,"median":-5.209018,"eighty":-0.550941,"high":-0.370531,"avg":-4.785109,"sd":3.633615,"marketCap":19516184},"quantilePoints":[{"date":"2024-04-05","current":-4.597074,"twenty":-4.75645,"median":-4.597074,"eighty":-3.952906,"marketCap":247060524},{"date":"2024-04-12","current":-5.285192,"twenty":-4.79019,"median":-4.726928,"eighty":-4.38975,"marketCap":284042061},{"date":"2024-04-19","current":-5.411717,"twenty":-5.438798,"median":-4.767993,"eighty":-4.57532,"marketCap":290841892},{"date":"2024-04-26","current":-6.268535,"twenty":-5.702502,"median":-5.138689,"eighty":-4.700069,"marketCap":336889870},{"date":"2024-05-03","current":-5.72026,"twenty":-5.938238,"median":-5.411717,"eighty":-4.727594,"marketCap":307423936},{"date":"2024-05-10","current":-5.948893,"twenty":-5.966207,"median":-5.603724,"eighty":-4.749348,"marketCap":319711350},{"date":"2024-05-17","current":-6.881182,"twenty":-6.171755,"median":-5.72026,"eighty":-4.765329,"marketCap":369815368},{"date":"2024-05-24","current":-6.526024,"twenty":-6.419477,"median":-5.852334,"eighty":-4.856783,"marketCap":350728123},{"date":"2024-05-31","current":-7.119566,"twenty":-6.557988,"median":-5.896729,"eighty":-4.946904,"marketCap":326617228},{"date":"2024-06-07","current":-5.417118,"twenty":-6.655355,"median":-5.948893,"eighty":-5.16799,"marketCap":248515704},{"date":"2024-06-14","current":-5.122964,"twenty":-6.625166,"median":-5.89118,"eighty":-5.079231,"marketCap":235021098},{"date":"2024-06-21","current":-4.172821,"twenty":-6.589953,"median":-5.833467,"eighty":-4.901621,"marketCap":191432327},{"date":"2024-06-28","current":-3.969777,"twenty":-6.557988,"median":-5.738018,"eighty":-4.86516,"marketCap":182117467},{"date":"2024-07-05","current":-4.511228,"twenty":-6.526024,"median":-5.680305,"eighty":-4.760002,"marketCap":206957095},{"date":"2024-07-12","current":-5.841429,"twenty":-6.49406,"median":-5.603724,"eighty":-4.798567,"marketCap":267981374},{"date":"2024-07-15","current":-6.825412,"twenty":-6.526024,"median":-5.660327,"eighty":-4.813855,"marketCap":313122622},{"date":"2024-08-02","current":-9.884093,"twenty":-6.542006,"median":-5.670316,"eighty":-4.829142,"marketCap":453442638},{"date":"2024-08-09","current":-7.500596,"twenty":-6.710706,"median":-5.738018,"eighty":-4.87207,"marketCap":427886482},{"date":"2024-08-16","current":-7.75207,"twenty":-6.825412,"median":-5.856316,"eighty":-4.928392,"marketCap":442232352},{"date":"2024-08-23","current":-8.155846,"twenty":-7.24299,"median":-5.902278,"eighty":-4.94491,"marketCap":465266543},{"date":"2024-08-30","current":-8.295371,"twenty":-7.548702,"median":-6.028804,"eighty":-4.98294,"marketCap":473226002},{"date":"2024-09-06","current":-9.684274,"twenty":-7.772364,"median":-6.120922,"eighty":-4.998807,"marketCap":552458796},{"date":"2024-09-13","current":-9.610284,"twenty":-8.191784,"median":-6.244914,"eighty":-5.018839,"marketCap":548237871},{"date":"2024-09-20","current":-9.971779,"twenty":-8.294103,"median":-6.360654,"eighty":-5.041746,"marketCap":568860105},{"date":"2024-09-27","current":-9.599714,"twenty":-8.935493,"median":-6.526024,"eighty":-5.050076,"marketCap":547634882},{"date":"2024-10-04","current":-9.037388,"twenty":-9.107996,"median":-6.621961,"eighty":-5.093809,"marketCap":515555851},{"date":"2024-10-11","current":-9.978122,"twenty":-9.382394,"median":-6.703603,"eighty":-5.220301,"marketCap":569221899},{"date":"2024-10-18","current":-10.49394,"twenty":-9.484712,"median":-6.794175,"eighty":-5.315929,"marketCap":598647777},{"date":"2024-10-25","current":-10.06691,"twenty":-9.672968,"median":-6.825412,"eighty":-5.346971,"marketCap":574287009},{"date":"2024-10-31","current":-9.792089,"twenty":-9.748541,"median":-7.119566,"eighty":-5.360507,"marketCap":558609287},{"date":"2024-11-08","current":-9.443128,"twenty":-9.802236,"median":-7.283651,"eighty":-5.372344,"marketCap":572357443},{"date":"2024-11-15","current":-7.16039,"twenty":-9.789552,"median":-7.500596,"eighty":-5.379633,"marketCap":433998376},{"date":"2024-11-22","current":-5.434099,"twenty":-9.773909,"median":-7.256318,"eighty":-5.396215,"marketCap":329366155},{"date":"2024-11-29","current":-5.407973,"twenty":-9.752346,"median":-7.139978,"eighty":-5.371303,"marketCap":327782663},{"date":"2024-12-06","current":-4.760865,"twenty":-9.734588,"median":-6.825412,"eighty":-5.339276,"marketCap":288560806},{"date":"2024-12-13","current":-0.854102,"twenty":-9.716407,"median":-6.794175,"eighty":-5.114636,"marketCap":51767979},{"date":"2024-12-20","current":-0.671224,"twenty":-9.680505,"median":-6.703603,"eighty":-5.031844,"marketCap":40683541},{"date":"2024-12-27","current":-0.719455,"twenty":-9.66543,"median":-6.637987,"eighty":-4.975898,"marketCap":43606909},{"date":"2025-01-03","current":-0.69333,"twenty":-9.621313,"median":-6.605935,"eighty":-4.929676,"marketCap":42023418},{"date":"2025-01-10","current":-0.657156,"twenty":-9.603942,"median":-6.526024,"eighty":-4.86516,"marketCap":39830892},{"date":"2025-01-17","current":-0.631031,"twenty":-9.545173,"median":-6.362567,"eighty":-4.746844,"marketCap":38247401},{"date":"2025-01-24","current":-0.677253,"twenty":-9.492745,"median":-6.288512,"eighty":-4.6939,"marketCap":41048962},{"date":"2025-01-31","current":-0.655147,"twenty":-9.465263,"median":-6.219701,"eighty":-4.511228,"marketCap":39709085},{"date":"2025-02-07","current":-0.63505,"twenty":-9.453365,"median":-6.05877,"eighty":-3.980076,"marketCap":38491015},{"date":"2025-02-14","current":-0.538587,"twenty":-9.43896,"median":-5.948893,"eighty":-0.813105,"marketCap":32644278},{"date":"2025-02-21","current":-0.488345,"twenty":-9.423405,"median":-5.89118,"eighty":-0.724279,"marketCap":29599103},{"date":"2025-02-28","current":-0.450162,"twenty":-9.384931,"median":-5.843753,"eighty":-0.704182,"marketCap":27284770},{"date":"2025-03-07","current":-0.468249,"twenty":-9.351106,"median":-5.738018,"eighty":-0.689713,"marketCap":28381033},{"date":"2025-03-14","current":-0.470191,"twenty":-9.227225,"median":-5.670316,"eighty":-0.675243,"marketCap":22443611},{"date":"2025-03-21","current":-0.53152,"twenty":-9.18875,"median":-5.509385,"eighty":-0.665195,"marketCap":25371039},{"date":"2025-03-28","current":-0.482968,"twenty":-9.161872,"median":-5.425609,"eighty":-0.655147,"marketCap":23053492},{"date":"2025-04-04","current":-0.408861,"twenty":-9.091808,"median":-5.407973,"eighty":-0.643893,"marketCap":19516184},{"date":"2025-04-11","current":-0.429305,"twenty":-9.050837,"median":-5.380674,"eighty":-0.631433,"marketCap":20491993},{"date":"2025-04-17","current":-0.472746,"twenty":-9.045443,"median":-5.362133,"eighty":-0.622992,"marketCap":22565587},{"date":"2025-04-25","current":-0.472746,"twenty":-9.037388,"median":-5.336421,"eighty":-0.57878,"marketCap":22565587},{"date":"2025-05-01","current":-0.408861,"twenty":-8.94268,"median":-5.209018,"eighty":-0.550941,"marketCap":19516184}],"updateTime":1746190907208}}}